CytRx Corporation (CYTR) Reviewed By Analysts


CytRx Corporation (CYTR) Reviewed By Analysts

These analysts have also projected a Low Estimate of $-0.11/share and a High Estimate of $-0.11/share.

According to Finviz Stock Screener, CytRx Corporation (NASDAQ:CYTR) traded with the volume of 1.16 Million in the previous trading session. The stock's market capitalization is 40.98M.

The Stock now has the market capitalization of $47.07 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 5.74% and monthly volatility of 5.82% respectively.

CytRx Corporation had its "outperform" rating reiterated by analysts at FBR Capital Markets. Shares of CytRx Corporation (NASDAQ:CYTR) now have an ABR of 2.00, derived from a total of 2 opinions.

Zacks Investment Research raised shares of CytRx from a "hold" rating to a "buy" rating and set a $0.50 price target for the company in a research note on Tuesday, November 15th. (NYSE:CYH) closed down -0.21 points or -2.24% at $9.18 with 3.06 mln shares exchanging hands. During the last trade, stock's minimum price has been reached out at $0.41 while the maximum trading price moved at $0.43.

CytRx Corporation Gross Margin percentage stands at 0% while its Operating Margin for trailing twelve month is 0 percent and Profit margin (ttm) is 0 Percent.

Several analysts are now covering the company. The Company recognized revenue related to 16 AUGMENT treatments in the fourth quarter of 2016, and related to 107 AUGMENT treatments in the full year 2016, including treatments offered under various pricing programs. CytRx Corporation P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

CytRx Corporation has 1 year price target of $2.38. This decrease was primarily driven by a $7.2 million decrease in stock-based compensation expense related to certain senior executives that did not recur in 2016 as a result of executive leadership changes in 2016, as well as certain mark-to-market adjustments of Founders' stock, which was fully vested and expensed in the first quarter of 2015 and did not recur in 2016, a $4.2 million decrease in costs related to global expansion preparation, including the establishment of certain worldwide legal entities and worldwide infrastructure, partially offset by a $4.7 million increase in costs related to commercialization efforts and overall business expansion, including increased marketing-related costs, and a $4.3 million increase in employee compensation and related benefits driven by the hiring of additional selling, general and administrative personnel. The stock stands almost $12.09 off versus the 52-week high of $21.38 and $5.14 above the 52-week low of $4.15. The company has Relative Strength Index (RSI 14) of 38.96 along with Average True Range (ATR 14) of 0.02. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Current price places the company's stock -1.69% away from its 200-day simple moving average, 24.71%, away from the 50-day average and also 5.08% away from 20-day average. The Stock has YTD (year to date) performance of 11.62 percent.